Skip to main content

Tecan Places Hyb System, High-Resolution Scanners in ASU Personal Dx Center


Austrian tools vendor Tecan announced this week that Arizona State University researchers have acquired one of its hybridization systems and two of its scanners for the purpose of processing protein microarrays.

The HS 4800 Pro automated hyb station and two of Tecan's PowerScanner units were placed in the Virginia G. Piper Center for Personalized Diagnostics at ASU's Biodesign Institute. Joshua LaBaer, director of the center, said in a statement that the instruments will be used to synthesize proteins for analysis.

According to LaBaer, the center's approach involves printing the genes for the desired proteins on slides and then adding a cell-free extract that synthesizes the proteins in situ. "The proteins are made literally an hour before we test them," LaBaer said.

He described the Tecan additions as "real workhorses," as the HS 4800 Pro allows the center's researchers to "produce proteins in situ on the glass, wash them off, and even incubate them with samples, all in a single run, without any manual intervention at all." He added that ASU selected the PowerScanners because of their "combination of good autoloading features, images and software."

Tecan has been active in the proteomics arena in recent years. Last October, the company inked a co-marketing agreement with Berlin-based JPT Peptide Technologies. Under that agreement, Tecan and JPT will market JPT's PepStar catalog peptide arrays and services alongside Tecan's HS 4800 Pro and HS 400 Pro automated array hybridization stations (BAN 10/2/2012).

And in June 2011, Tecan announced that it had developed a sample preparation system in collaboration with the Translational Genomics Research Institute and the Biodesign Institute at ASU for proteomic biomarker discovery and validation.

Company representatives have told BioArray News in the past that protein array users represent its largest customer segment (BAN 6/1/2010).

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.